FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387206816> ?p ?o ?g. }

• W4387206816 endingPage "e155" @default.
• W4387206816 startingPage "e155" @default.
• W4387206816 abstract "The brain is a common site for metastases. Resection of large or symptomatic metastases is followed by stereotactic radiotherapy to prevent local recurrence. The optimal fractionation scheme is subject of ongoing research. Supported by emerging retrospective data, we hypothesize that hypofractionated stereotactic radiotherapy (HFSRT) is superior to single-fraction stereotactic radiosurgery (SRS) in terms of local control (LC). We designed the SATURNUS trial to prospectively demonstrate the superiority of HFSRT over SRS after resection of brain metastases in terms of LC.The SATURNUS trial is a prospective, randomized phase III trial, currently recruiting patients at a single institution. Patients are 1:1 allocated to HFSRT or SRS using permuted block randomization. Affiliation to the treatment arm is solely blinded to the neuroradiologist assessing therapy response. HFSRT will be delivered with 6 - 7 x 5 Gy and SRS with 1 x 12-20 Gy, prescribed to the surrounding isodose, depending on cavity size and proximity to structures at risk. For SRS, doses do not exceed the maximum doses according to RTOG 90-05. Case number calculation was based on own institutional data on HFSRT (mean LC rate of 88% at 12 months) and data from large phase III trials on SRS (pooled mean LC rate of 66% at 12 months). Using a Chi-squared test of equal proportions (odds ratio = 1), setting test significance level (α) to 0.05, and allocating an equal number of patients to both treatment arms, 114 patients are needed to detect the superiority of HFSRT in terms of LC at 12 months (primary endpoint) with a power of at least 80%. Estimating a dropout rate of 10%, the case number was set to 126. The trial was registered with clinicaltrials.gov (NCT05160818). The first patient was enrolled in May 2021 and recruitment is ongoing. Patients with up to three resected brain metastases are considered for study participation. Further eligibility criteria are histologically confirmed solid tumor disease, resection cavity diameter ≤ 4 cm, consent to perform adjuvant radiotherapy by an interdisciplinary tumor board, completed wound healing, resection within the last six weeks at the time of study inclusion, age ≥ 18 years, KPS ≥ 60%, adequate contraceptive measures for fertile women / men and written informed consent. Patients are followed up clinically and with MRI at 6 weeks and 3, 6, 9 and 12 months after treatment. LC is assessed according to RANO-BM. Toxicity (CTCAE v4.03) is assessed as a secondary endpoint. The rather broad dose corridors allowed within the trial do justice to clinical reality, however, may represent a limitation of the trial. They are therefore addressed with a predefined subgroup analysis, as will be cavity size, among others. Participation of further study centers is desired. To the best of our knowledge, the SATURNUS trial is the only randomized phase III trial adequately powered to detect the superiority of HFSRT over SRS with regard to LC for resected brain metastases.To be determined.To be determined." @default.
• W4387206816 created "2023-09-30" @default.
• W4387206816 creator A5022656280 @default.
• W4387206816 creator A5031482336 @default.
• W4387206816 creator A5032259979 @default.
• W4387206816 creator A5036856462 @default.
• W4387206816 creator A5039985608 @default.
• W4387206816 creator A5056609184 @default.
• W4387206816 creator A5072010197 @default.
• W4387206816 creator A5073926740 @default.
• W4387206816 creator A5085312364 @default.
• W4387206816 date "2023-10-01" @default.
• W4387206816 modified "2023-10-17" @default.
• W4387206816 title "Hypofractionated Stereotactic Radiotherapy vs. Single Fraction Stereotactic Radiosurgery to the Resection Cavity of Brain Metastases after Surgical Resection (SATURNUS trial): A Prospective, Randomized Phase III Trial" @default.
• W4387206816 doi "https://doi.org/10.1016/j.ijrobp.2023.06.979" @default.
• W4387206816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784743" @default.
• W4387206816 hasPublicationYear "2023" @default.
• W4387206816 type Work @default.
• W4387206816 citedByCount "0" @default.
• W4387206816 crossrefType "journal-article" @default.
• W4387206816 hasAuthorship W4387206816A5022656280 @default.
• W4387206816 hasAuthorship W4387206816A5031482336 @default.
• W4387206816 hasAuthorship W4387206816A5032259979 @default.
• W4387206816 hasAuthorship W4387206816A5036856462 @default.
• W4387206816 hasAuthorship W4387206816A5039985608 @default.
• W4387206816 hasAuthorship W4387206816A5056609184 @default.
• W4387206816 hasAuthorship W4387206816A5072010197 @default.
• W4387206816 hasAuthorship W4387206816A5073926740 @default.
• W4387206816 hasAuthorship W4387206816A5085312364 @default.
• W4387206816 hasConcept C126322002 @default.
• W4387206816 hasConcept C126838900 @default.
• W4387206816 hasConcept C141071460 @default.
• W4387206816 hasConcept C155806632 @default.
• W4387206816 hasConcept C156957248 @default.
• W4387206816 hasConcept C168563851 @default.
• W4387206816 hasConcept C188816634 @default.
• W4387206816 hasConcept C204243189 @default.
• W4387206816 hasConcept C2780387249 @default.
• W4387206816 hasConcept C2989005 @default.
• W4387206816 hasConcept C2992393070 @default.
• W4387206816 hasConcept C509974204 @default.
• W4387206816 hasConcept C71924100 @default.
• W4387206816 hasConceptScore W4387206816C126322002 @default.
• W4387206816 hasConceptScore W4387206816C126838900 @default.
• W4387206816 hasConceptScore W4387206816C141071460 @default.
• W4387206816 hasConceptScore W4387206816C155806632 @default.
• W4387206816 hasConceptScore W4387206816C156957248 @default.
• W4387206816 hasConceptScore W4387206816C168563851 @default.
• W4387206816 hasConceptScore W4387206816C188816634 @default.
• W4387206816 hasConceptScore W4387206816C204243189 @default.
• W4387206816 hasConceptScore W4387206816C2780387249 @default.
• W4387206816 hasConceptScore W4387206816C2989005 @default.
• W4387206816 hasConceptScore W4387206816C2992393070 @default.
• W4387206816 hasConceptScore W4387206816C509974204 @default.
• W4387206816 hasConceptScore W4387206816C71924100 @default.
• W4387206816 hasIssue "2" @default.
• W4387206816 hasLocation W43872068161 @default.
• W4387206816 hasLocation W43872068162 @default.
• W4387206816 hasOpenAccess W4387206816 @default.
• W4387206816 hasPrimaryLocation W43872068161 @default.
• W4387206816 hasRelatedWork W2084539146 @default.
• W4387206816 hasRelatedWork W2101745801 @default.
• W4387206816 hasRelatedWork W2109622655 @default.
• W4387206816 hasRelatedWork W2143921754 @default.
• W4387206816 hasRelatedWork W2379084329 @default.
• W4387206816 hasRelatedWork W2388910868 @default.
• W4387206816 hasRelatedWork W2530945448 @default.
• W4387206816 hasRelatedWork W2603200509 @default.
• W4387206816 hasRelatedWork W2810235317 @default.
• W4387206816 hasRelatedWork W2903232234 @default.
• W4387206816 hasVolume "117" @default.
• W4387206816 isParatext "false" @default.
• W4387206816 isRetracted "false" @default.
• W4387206816 workType "article" @default.